Affinity Asset Advisors’s Innate Pharma IPHA Stock Holding History

Affinity Asset Advisors’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-125,000	Closed	-$771K	–	64
2021 Q3	$771K	Buy	+125,000	New	+$539K	0.19%	63

Other funds holding IPHA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Affinity Asset Advisors's IPHA Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Innate Pharma (IPHA) in Q4 2021, closing a stake of 125,000 shares — an estimated $771K sold.

Affinity Asset Advisors first reported a position in IPHA in Q3 2021 and held it in 1 quarter. The position peaked at $771K in Q3 2021. 16 funds tracked by Wall St. Rank hold IPHA as of Q4 2021.

Affinity Asset Advisors reported no remaining Innate Pharma position as of Q4 2021 after selling out during the quarter.
Affinity Asset Advisors sold 125,000 Innate Pharma shares in Q4 2021, an estimated $771K.
Affinity Asset Advisors first reported a position in Innate Pharma in Q3 2021 and held it in 1 quarter.
Affinity Asset Advisors's Innate Pharma position peaked at $771K in Q3 2021.
16 funds tracked by Wall St. Rank held Innate Pharma as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.